Literature DB >> 10192407

Tardive dyskinesia in affective disorders.

J M Kane1.   

Abstract

Soon after the introduction of antipsychotic drugs into clinical practice, these agents were observed to be capable of producing not only acute extrapyramidal ("parkinsonian") side effects, but also later occurring abnormal involuntary movements that came to be called tardive dyskinesia. Since antipsychotic drugs are used in a variety of conditions that include psychotic features, studies have attempted to determine whether specific diagnostic subgroups may experience different degrees of vulnerability to drug-induced movement disorders. This issue is important not only to inform clinical practice, but also to provide clues to pathophysiology. A number of studies suggest that patients with affective disorders are at greater risk for developing tardive dyskinesia (controlling, to the extent possible, for other relevant variables such as age, sex, length of treatment). Encouraging preliminary data with new antipsychotic drugs such as olanzapine suggest that the risk of tardive dyskinesia associated with long-term antipsychotic drug use may be substantially reduced. This would go a long way toward improving the benefit-to-risk ratio of antipsychotic drug treatment, particularly in patients with affective disorders.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10192407

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  12 in total

1.  Adjunctive olanzapine treatment in bipolar adolescents responding insufficiently to mood stabilizers. Four case reports.

Authors:  F Neslihan Inal Emiroglu; Ozlem Gencer; Aylin Ozbek
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-05-26       Impact factor: 4.785

Review 2.  Olanzapine: a review of its use in the treatment of bipolar I disorder.

Authors:  N Bhana; C M Perry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 3.  Atypical antipsychotics and mood stabilization in bipolar disorder.

Authors:  Paolo Brambilla; Francesco Barale; Jair C Soares
Journal:  Psychopharmacology (Berl)       Date:  2003-02-27       Impact factor: 4.530

Review 4.  Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review.

Authors:  Keming Gao; David E Kemp; Stephen J Ganocy; Prashant Gajwani; Guohua Xia; Joseph R Calabrese
Journal:  J Clin Psychopharmacol       Date:  2008-04       Impact factor: 3.153

Review 5.  Adverse effects of atypical antipsychotics : differential risk and clinical implications.

Authors:  Peter M Haddad; Sonu G Sharma
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

6.  The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression.

Authors:  Daniel M Blumberger; Benoit H Mulsant; Dora Kanellopoulos; Ellen M Whyte; Anthony J Rothschild; Alastair J Flint; Barnett S Meyers
Journal:  J Clin Psychopharmacol       Date:  2013-06       Impact factor: 3.153

7.  The neuropharmacology of psychosis.

Authors:  Carol A Tamminga; John M Davis
Journal:  Schizophr Bull       Date:  2007-06-11       Impact factor: 9.306

8.  An open label follow-up study on amisulpride in the add-on treatment of bipolar I patients.

Authors:  Mauro Giovanni Carta; Fausta Zairo; Gisa Mellino; Maria Carolina Hardoy; Eduard Vieta
Journal:  Clin Pract Epidemiol Ment Health       Date:  2006-08-24

9.  Combination quetiapine therapy in the long-term treatment of patients with bipolar I disorder.

Authors:  M C Hardoy; Alessandra Garofalo; Bernardo Carpiniello; J R Calabrese; M G Carta
Journal:  Clin Pract Epidemiol Ment Health       Date:  2005-07-18

10.  Revisiting loxapine: a systematic review.

Authors:  Dina Popovic; Philippe Nuss; Eduard Vieta
Journal:  Ann Gen Psychiatry       Date:  2015-04-01       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.